lo and therefore failed to resist the inhibition of Foxp3 expression in response to effector cell-differentiating cytokines. Thus, DCs require BTLA and CD5-dependent mechanisms to actively adjust tolerizing T cell responses under steady-state conditions.
. In the steady state, defined by the absence of pro-inflammatory stimuli, the outcome of T cell activation by DCs results in T cell tolerance (Hawiger et al., 2001; Ohnmacht et al., 2009; Probst et al., 2003; Steinman et al., 2003) . Further, specialized types of DCs have tolerogenic functions (Belz et al., 2002; Coombes et al., 2007; Gottschalk et al., 2013; Idoyaga et al., 2013) . However, potentially tolerogenic CD8 + , CD103 + , or DEC205 + DCs constitute only relatively minor subpopulations among all CD11c + DCs in the lymphoid organs. Therefore, the relevance of tolerogenic functions by such DCs remains unclear in the context of T cell responses to specific antigens that are also being presented by other DCs.
Foxp3-expressing (Foxp3 + ) peripheral (p) regulatory T (Treg) cells converted by DCs in steady state from extrathymic T cells, which induce de novo Foxp3 expression, prevent specific subsequent autoimmune responses (Coombes et al., 2007; Hadeiba et al., 2008; Jones et al., 2015; Josefowicz et al., 2012b; Kretschmer et al., 2005; Sun et al., 2007) . Tolerogenic DCs that induce Treg cells are characterized by production of various immunomodulatory metabolites and cytokines (Coombes et al., 2007; Li and Flavell, 2008; Manicassamy et al., 2009; Mascanfroni et al., 2013; Mucida et al., 2007; Munn et al., 2002) . Further, specific immunomodulatory molecules, such as CTLA-4 and PD-L1, function in tolerance and Treg cell induction by DCs (Fife et al., 2009; Francisco et al., 2009; Probst et al., 2005; Wang et al., 2008; Wing et al., 2008) . B and T lymphocyte associated (BTLA), an immunoglobulin domain superfamily protein, is expressed in T cells and antigen-presenting cells, including CD8 + DCs, where it acts as a ligand for the herpesvirus entry mediator (HVEM), a tumor necrosis factor receptor superfamily member expressed in resting and activated T cells (Cheung et al., 2005; Murphy and Murphy, 2010; Steinberg et al., 2013; Watanabe et al., 2003) . The functions of HVEM and BTLA can govern T cell responses, including their memory and regulatory functions (Flynn et al., 2013; Huarte et al., 2016; Sharma et al., 2014; Soroosh et al., 2011) .
In addition to extrinsic signals, a conversion of pTreg cells is mediated by the intrinsic specificity to self and tolerizing antigens. Self-reactive T cells are characterized by increased expression of CD5 that promotes conversion of such CD5 hi cells into Foxp3 + pTreg cells by blocking mTOR activated in response to effector cell-differentiating cytokines . Therefore, CD5 selectively regulates induction of Treg cells without compromising an overall high plasticity of immune responses among a total T cell repertoire. The expression of CD5 in T cells increases in response to either self-peptide(p) MHC in the thymus or tolerizing antigens presented by DCs in the periphery (Azzam et al., 1998; Hawiger et al., 2004) . The expression of CD5 in T cells exiting the thymus represents a spectrum rather than discrete amounts, and therefore, specific upregulation of CD5 expression in T cells by peripheral DCs may be crucial for instructing the conversion of extrathymic Treg cells (Azzam et al., 2001; Hawiger et al., 2004; Henderson et al., 2015) . This raises a question of how such a tolerogenic upregulation of CD5 expression in T cells is governed to ensure a specific induction of Treg cells in response to tolerizing antigens presented by DCs.
Here, we show that efficient induction of Treg cells relies on a specific T cell stimulation by DCs that use BTLA-and (Hawiger et al., 2004; Idoyaga et al., 2013; Jones et al., 2015; Yogev et al., 2012) . To examine the impact on such tolerance by antigens that are acquired and presented by the entire population of CD11c + DCs, we developed a recombinant chimeric antibody (denoted here as aCD11c-MOG) to deliver MOG peptide to all CD11c + DCs in vivo. CD11c mediates efficient antigen uptake for presentation to T cells (Castro et al., 2008) . To help exclude a non-specific targeting by aCD11c-MOG, we used the same mutated mouse heavy and light constant regions that we previously designed for the highly specific aDEC-MOG that delivers MOG to DEC205 + DCs (Hawiger et al., 2001; Hawiger et al., 2004) Figures S1B-S1D ). We then pre-treated multiple groups of B6 mice with aCD11c-MOG and aDEC-MOG 6 weeks before we immunized such mice with MOG 35-55 in adjuvant to induce EAE. In agreement with previously published results (Hawiger et al., 2004; Jones et al., 2015) , MOG delivered to DEC205 + DCs prevented EAE and spinal cord T cell infiltrations. In contrast, a treatment with MOG delivered to all CD11c + DCs had no impact on subsequently induced EAE ( Figures 1A and 1B) . We conclude that antigens available to all CD11c + DCs fail to provide long-lasting specific tolerance. The pTreg cells induced de novo by DCs are required for longlasting tolerance to block responses by newly enlisted encephalitogenic T cells . Figures S1F and S1G ). Also, mice pre-treated with aCD11c-MOG became resistant to EAE induced 1 week later ( Figure S1H ). However, in the absence of the de novo conversion of pTreg cells, this CD11c + DC-induced tolerance was only transient, and mice became susceptible to EAE within 6 weeks ( Figures 1A and 1B) . Overall, we conclude that T cell activation by all CD11c + DCs in steady state leads to a transient unresponsiveness of T cells that do not persist and fail to differentiate into pTreg cells to prevent a subsequent antigenic challenge.
To further extend our studies, we developed aCD11c-OVA (Experimental Procedures). We then examined cognate (A, B, D, F, and H) Graphs show mean ± SEM, *p < 0.05, **p < 0.01, ***p < 0.001, and ****p < 0.0001 determined by one-way or two-way ANOVA, n = number of mice per group from two to four independent experiments. Please see also Figure S1 .
OVA-specific (OTII) T cell responses to OVA peptide delivered to either all CD11c + DCs or only DEC205 + DCs using aDEC-OVA. As expected, we found about 21% of pTreg cells within 12 days after treatment with aDEC-OVA. In contrast, we found only negligible numbers of pTreg cells after treatment with aCD11c-OVA ( Figures 1G and 1H ) despite a similar activation of T cells in aDEC-OVA and aCD11c-OVAtreated groups ( Figure S1I ). We conclude that CD11c we used Batf3 À/À mice, characterized by reduced numbers of these DCs (Hildner et al., 2008) . 12 and 21 days after a treatment with aDEC-MOG, we observed, correspondingly, only about 5%-10% and 13% conversion of specific T cells into pTreg cells in the Batf3 À/À mice, whereas the pTreg cell induction in Batf3 +/+ mice remained at about 22% and 36%, respectively (Figures 2A-2D ). Therefore, similar to the functions in thymus (Perry et al., 2014) (Persson et al., 2013; Schlitzer et al., 2013) . We found that, in Irf4 À/À mice treated with aCD11c-MOG, the pTreg cell conversion rate increased about 3-to 6-fold compared to the corresponding pTreg cell induction in Irf4 +/+ mice despite similar (Figures S3F and S3G) . This was accompanied in cultured DCs by a partial, non-specific downregulation of BTLA expression consistent with its moderate impact on in vitro iTreg cell induction ( Figure S3H ). In contrast to specific functions of BTLA in DCs, we observed a similar conversion of pTreg cells from Btla À/À or Btla +/+ T cells in vivo ( Figures S3I and S3J ). We collectively conclude that BTLA promotes an efficient de novo conversion of Treg cells by DCs.
A genetic deletion of BTLA increases the severity of EAE (Watanabe et al., 2003) . Therefore, to examine the role of BTLA in specific anti-EAE tolerance, we pre-treated B6 mice with aDEC-MOG, followed by a treatment with aBTLA. After 6 weeks, we then immunized such mice to induce EAE. We observed a similar EAE induction in groups pre-treated with either 6A6 aBTLA antibody or an isotype control in the absence of MOG targeting to DCs, consistent with a lack of an impact of a transient blockade of BTLA on EAE induced 6 weeks later. In contrast, in mice treated with aDEC-MOG, despite an initial resistance to EAE, a concomitant blocking of BTLA abolished the DC-induced anti-EAE tolerance in agreement with the role of BTLA in induction by DCs of pTreg cells to efficiently inhibit EAE ( Figures 3F  and 3G ).
BTLA and HVEM Function to Upregulate CD5 Expression in Peripheral T Cells 2D2 T cells in mice treated with aDEC-MOG respond with an increased expression of CD5 that precedes a de novo induction of Foxp3 expression . In contrast, we found an unaltered expression of CD5 in T cells from mice treated with either PBS or aCD11c-MOG ( Figure S4A) (C, E, F, and G) Graphs show mean ± SEM, *p < 0.05, **p < 0.01, and ***p < 0.001 determined by one-way or two-way ANOVA, n = number of mice per group from two to three independent experiments. Please see also Figure S3 .
To investigate if engagement of HVEM, a receptor for BTLA, upregulates expression of CD5, we cross-linked HVEM in naive sorted Foxp3 neg CD25 neg 2D2 and polyclonal CD4 + T cells also activated through TCR stimulation. We found that an additional engagement of HVEM upregulated surface expression of CD5 and increased Cd5 gene expression (Figures S4D , 4C, and 4D). HVEM can govern multiple signaling pathways in immune and epithelial cells (Shui et al., 2011 (Shui et al., , 2012 Steinberg et al., 2011) . In developing CD5 hi T cells, a specific engagement of HVEM had no impact on STAT3 phosphorylation and a minimal impact on TCR-induced NFkB activation (Figures S4E-S4G ). In contrast, HVEM engagement increased phosphorylation of mitogen-activated protein kinase (MAPK) kinase (MEK) ( Figure 4E ). MEK activation can increase expression of E26 avian leukemia oncogene 1 (ETS1), as well as decrease an expression of transcription factor 3 (TCF-3, also known as E2A or E47), correspondingly, positive and negative regulators of Cd5 expression (Khanna et al., 2011; Page et al., 2004; Paumelle et al., 2002; Tung et al., 2001; Yang et al., 2004) . We found a decreased expression of E2A (E47) and an increased expression and abundance of ETS1 in developing CD5 hi T cells, consistent with their specific functions in transcriptional regulation of Cd5 expression ( Figures 4F-4H ). We conclude that HVEM governs in developing CD5 hi T cells pathways regulating expression of CD5. 
DISCUSSION
In this study, we have identified a crucial mechanism governing induction of extrathymic Treg cells and tolerance by DCs. In T cells, BTLA-and HVEM-mediated functions increase the expression of CD5 to instruct Treg cell differentiation. Thus, only T cells specifically activated by BTLA + DEC205 + CD8 + DCs efficiently convert into tolerogenic pTreg cells. In contrast, Treg cell conversion is impaired in T cells that respond to antigens presented by the majority of CD11c + DCs that are BTLA neg .
CD11c + DCs in lymphoid tissues constitute phenotypically heterogeneous populations whose development is dependent on distinct transcription factors (Satpathy et al., 2012) . This diversity matches the versatile T cell responses induced by such DCs (Guilliams et al., 2014; Mellman, 2013; Steinman, 2012) . In the pro-inflammatory environment, priming of T cells by DCs leads to immune responses. In contrast, the presentation of antigens by DCs in steady state can result in multiple mechanisms of T cell tolerance (Hawiger et al., 2001; Ohnmacht et al., 2009; Probst et al., 2003; Steinman et al., 2003) . However, a broad tolerogenic outcome of antigenic presentation by DCs in steady state could hamper subsequent protective immune responses against cross-reactive antigens. Therefore, induction of tolerance by DCs may rather be mediated by specialized ''tolerogenic'' DCs to enhance the specificity of such immune regulation (Coquerelle and Moser, 2010; Merad et al., 2013 ). Yet, despite the proposed tolerance-inducing functions of some DCs, a precise functional definition of tolerogenic DCs remains elusive. The proposed populations of tolerogenic DCs expressing CD8, DEC205, or CD103 include the ''lymphoid resident'' DCs and migratory DCs that transfer peripheral antigens to the lymphoid tissues (Coquerelle and Moser, 2010; Lukacs-Kornek and Turley, 2011; Merad et al., 2013; Randolph et al., 2008; Shortman and Heath, 2010) . However, it remains unknown if the induction of tolerance requires T cell activation by antigens whose presentation is restricted to tolerogenic DCs. Our findings, that only antigens presented specifically by BTLA + DEC205 + CD8 + DCs induce T cell tolerance, support a model of tolerance that relies on a compartmentalization of antigenic presentation by various DC types. Our results further indicate that, by governing the crucial tolerogenic functions of DCs, BTLA helps to further shape a plasticity of DC-mediated T cell responses determined by various pathways (Iwasaki and Medzhitov, 2015; Kumamoto et al., 2013; Sancho and Reis e Sousa, 2012; Segura and Amigorena, 2013; Steinman, 2012) . In contrast, the roles in specific immune responses of BTLA expressed solely in various types of immune cells require further investigation.
A conversion of Foxp3 + pTreg cells by DCs mediates tolerance, and induction of pTreg cells by DCs is independent of other potential antigen-presenting cells (Esterhá zy et al., 2016; Hawiger et al., 2010; Jones et al., 2015; Kretschmer et al., 2005) . Several mechanisms proposed to mediate the induction of Treg cells by DCs rely on specific cytokines and metabolites, as well as signaling by PD-1 and CTLA-4 (Coombes et al., 2007; Francisco et al., 2009; Li and Flavell, 2008; Manicassamy et al., 2009; Mascanfroni et al., 2013; Mucida et al., 2007; Probst et al., 2005; Sun et al., 2007; Wang et al., 2008; Yogev et al., 2012) . Although the relevant mechanisms by which these immunomodulatory pathways induce Foxp3 + Treg cells remain incompletely understood, such pathways may directly affect the cell-intrinsic mechanisms that induce Foxp3 expression (Benoist and Mathis, 2012; Josefowicz et al., 2012a) . However, the regulation of immune tolerance also depends on the specificity of T cells to self and tolerizing antigens as reflected by expression of CD5 (Azzam et al., 1998; Klein et al., 2014) . CD5 is a surface protein that recruits multiple positive and negative regulators of T cell signaling (Soldevila et al., 2011) . CD5 expression parallels T cell receptor (TCR) signal strength during thymic T cell development, leading to an increased CD5 expression in developing CD4 + T cells bearing high-affinity TCRs for self-antigens (Azzam et al., 1998) . Despite the functions of CD5 as a negative regulator of TCR signaling in thymus, the peripheral CD5 hi T cells remain responsive to antigenic stimulation and can form cross-reactive effector T cells, thereby risking the development of autoimmune responses (Klein et al., 2014; Mandl et al., 2013; Persaud et al., 2014) . Recently, we established that CD5 instructs the conversion of such self-reactive and potentially autoagressive extrathymic CD5 hi T cells into pTreg cells by modulating their responsiveness to effector cell-differentiating cytokines . In addition to thymic development, CD5 expression can also increase in response to peripheral tolerogenic signals (Hawiger et al., 2004) . Therefore, an upregulation of CD5 expression is a common mechanism for both thymic and peripheral processes to instruct subsequent induction of pTreg cells . However, in peripheral T cells, mechanisms governing the expression of CD5 and the impact of such mechanisms on tolerance remain unknown. Our results now indicate that only BTLA + DEC205 + CD8 + DCs specifically mediate a tolerizing upregulation of CD5 expression in T cells. Therefore, the antigens acquired and presented predominantly by these tolerogenic DCs may be perceived as ''tolerizing'' by T cells. In contrast, antigens that are available to all CD11c + DCs and are presented by a majority of non-tolerogenic BTLA neg DCs fail to provide a BTLAmediated signal to upregulate CD5 expression in T cells and do not alter the subsequent immune responses in steady state. Our results also reveal that HVEM, a receptor of BTLA expressed in T cells, governs expression of transcription factors ETS1 and E2A (E47) that regulate expression of CD5. Therefore, functions of BTLA and HVEM enable DCs to link the T cell responsiveness to specific tolerogenic antigens with a CD5-dependent process governing pTreg cell induction to maintain the de novo-induced peripheral T cell tolerance. In the absence of these specific functions of BTLA and CD5, the steady-state conditions alone may not facilitate a sufficient induction of tolerance by DCs. Therefore, we propose that, through the combined functions of BTLA and CD5, tolerogenic DCs can actively adjust T cell responses by favoring a differentiation of CD5 hi T cells that can more readily become tolerizing pTreg cells.
The differences in cytokine milieu between in vivo and ex vivo environments, as well as phenotypic alterations of DCs in vitro, may contribute to the specific variations of especially iTreg cell induction, also possibly regulated by multiple mechanisms (Wang et al., 2008; Yamazaki et al., 2008) . However, the functions of BTLA and HVEM are both necessary and sufficient to promote a differentiation of Treg cells that are crucial to govern T cell tolerance and prevention of autoimmunity by DCs in vivo.
In conclusion, by showing that induction of pTreg cells relies on specific DCs that use BTLA-and CD5-dependent mechanisms to actively adjust T cell responses, our findings help to further define and extend a concept of tolerogenic DCs. In contrast, a majority of CD11c + DCs are BTLA neg and, therefore, are not tolerogenic even in the steady state. Thus, a selective induction of pTreg cells by specialized tolerogenic functions of BTLA + DCs may promote tolerance while helping to maintain an overall high plasticity of immune responses among the total repertoire of T cells that respond to antigens presented by all DCs.
EXPERIMENTAL PROCEDURES
For complete experimental procedures, see the Supplemental Information.
Mice

Cd5
À/À (Tarakhovsky et al., 1994) , Foxp3 RFP (Wan and Flavell, 2005) , anti-MOG TCR transgenic (2D2) (Bettelli et al., 2003) , OTII TCR Tg (Barnden et al., 1998) , Batf3 À/À (Hildner et al., 2008) , Irf4 fl/fl (Klein et al., 2006) , ItgaxCre (Caton et al., 2007) , and Btla À/À (Watanabe et al., 2003) mice were previously described and are available from the Jackson Laboratory. All mice were bred on a CD45.1 or CD45.2 congenic C57BL/6 background. 6-to 8-week-old sex-and age-matched littermates were used for all experiments. All mice were maintained in our facility under specific pathogen free conditions and used in accordance with guidelines of the Saint Louis University Institutional Animal Care and Use Committee.
Chimeric Antibodies
Chimeric antibodies were produced as previously described (Hawiger et al., 2001 (Hawiger et al., , 2004 and also Supplemental Information. Chimeric antibodies were injected in PBS intraperitoneally (i.p.) at 15mg/mouse (MOG-delivering antibodies) or 125 ng/mouse (OVA-delivering antibodies) as established previously (Hawiger et al., 2004 (Hawiger et al., , 2010 
Cell Cultures
Lymph node and spleen cells were pooled, and CD4 + T cells were enriched using magnetic microbeads (Miltenyi) and then sorted on ARIA III (BD). 0.25 3 10 6 /well T cells were cultured with anti-CD3 (145-2C11) (1 mg/mL) and anti-CD28 (37.51) (1.5 mg/mL) in RPMI-1640 media containing 10% FBS, Penicillin-Streptomycin, L-Glutamine, b-Mercaptoethanol, Sodium pyruvate (GIBCO), recombinant IL-2 (200 units /ml), and, in some experiments, TGF-b
(1-4 ng/mL) (BioLegend). Anti-CD3 was cross-linked by addition of anti-Armenian Hamster IgG (15 mg/mL) after 20 min incubation at 37 C. In some experiments, recombinant IL-4 (2 ng/mL) or IL-6 (8 ng/mL) were additionally added. Additionally, anti-HVEM (HMHV-1B18) (BioLegend) or Isotype control (Armenian Hamster IgG) (BioXCell) were added to some cultures at 6 mg/mL or as indicated and were cross-linked by addition of anti-Armenian Hamster IgG (15 mg/mL) after 20 min incubation at 37 C. Alternatively, LNs and spleens were dissociated in 5% FCS RPMI and incubated in the presence of collagenase D (Roche) and EDTA as described before (Hawiger et al., 2001 (Hawiger et al., , 2004 , and CD11C + DCs were enriched using microbeads ( 
Statistical Analysis
In all experiments, data were pooled from two to four independent experiments, and individual p values were calculated using Student's t test with Welch's correction, one-way ANOVA, or two-way ANOVA.
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